Gastroenterology · Cholangiocarcinoma

CA 19-9 Test: Bile Duct Cancer Screening in PSC

At a Glance

The CA 19-9 blood test is a routine screening tool used every 6 to 12 months to monitor PSC patients for bile duct cancer. Elevated levels do not always mean cancer, as inflammation or jaundice can cause spikes. Testing is always paired with imaging scans for accurate diagnosis.

By checking your CA 19-9 levels regularly, along with taking images of your bile ducts, your care team is actively working to catch any early signs of bile duct cancer (cholangiocarcinoma or CCA) when it is most treatable ^[1]^[2]. Your doctor is ordering a CA 19-9 blood test every six months because it is a standard surveillance tool ^[3]. People living with Primary Sclerosing Cholangitis (PSC) have an estimated 10% to 20% lifetime risk of developing this type of cancer, making routine monitoring an essential part of your care ^[4]^[5].

What is CA 19-9?

CA 19-9 stands for Carbohydrate Antigen 19-9. It is a tumor marker—a substance that can be measured in your blood ^[3]. While healthy individuals have small amounts of CA 19-9, tumor cells often produce it in higher quantities. This makes the blood test a helpful early warning system, or biomarker, for your doctor to monitor ^[6]^[7].

How Screening Works in PSC

Because the risk of cholangiocarcinoma is a serious part of living with PSC, medical guidelines recommend regular surveillance ^[8]^[9].

The 6-to-12-Month Schedule: Most medical societies recommend that PSC patients undergo cancer screening every 6 to 12 months ^[8]^[1].
Pairing Blood Work with Scans: Standard practice is to pair the CA 19-9 blood test with an imaging scan, typically an ultrasound or an MRCP (Magnetic Resonance Cholangiopancreatography) ^[8]^[10]. While an ultrasound uses sound waves to view your liver, an MRCP is a specialized MRI that provides detailed pictures of your bile ducts ^[11]^[12]. Checking both the blood marker and the physical structure of your bile ducts gives your doctor the best chance of spotting dangerous changes early ^[1].

Important Things to Know About Your Results

When you look at your lab results, you will usually just see a number. Rather than focusing on a standard “normal” cutoff, your doctor will be looking at your personal baseline and watching for significant trends over time. Seeing an elevated CA 19-9 level can be frightening, but it does not automatically mean you have cancer ^[6].

Non-Cancer Causes: In PSC, your bile ducts are inflamed and often narrowed. A flare-up of inflammation, a bacterial infection in the bile ducts (cholangitis), or an ordinary bile blockage can cause CA 19-9 levels to spike temporarily ^[13]^[14].
Jaundice and Bilirubin: If you are experiencing jaundice (yellowing of the skin or eyes) or have high bilirubin (a yellowish pigment made during the normal breakdown of red blood cells) levels, your CA 19-9 is likely to be elevated as well ^[14]^[15].
False Negatives (Low Scores): On the flip side, a normal or low CA 19-9 score does not guarantee you are cancer-free. This is exactly why the imaging scan is also required ^[1].
The “Lewis Negative” Exception: About 5% to 10% of the population lacks a specific blood protein called the Lewis antigen. If you are “Lewis negative,” your body physically cannot produce CA 19-9, meaning your test results will always be near zero even if cancer is present.

What Happens if Your Level is Concerning?

If your CA 19-9 levels come back unusually high, your doctor will look at the whole picture. If you currently have an infection or jaundice, they may wait for it to clear and retest your blood later ^[14]. If the number remains consistently high or your doctor sees something suspicious on your ultrasound or MRCP, the next step is usually more detailed imaging or an ERCP (Endoscopic Retrograde Cholangiopancreatography). An ERCP uses a flexible tube sent down your throat to look directly at your bile ducts and, if necessary, take small tissue samples (a biopsy) to check for cancer cells.

By participating in these regular tests, you are taking an important and proactive step in managing your PSC and protecting your long-term health.

Common questions in this guide

Why do I need a CA 19-9 blood test if I have PSC?

Patients with Primary Sclerosing Cholangitis have an increased risk of developing bile duct cancer. The CA 19-9 blood test acts as a tumor marker and an early warning system to help doctors monitor for potential cancer cells when they are most treatable.

Does a high CA 19-9 level mean I have bile duct cancer?

No, an elevated CA 19-9 does not automatically mean you have cancer. In PSC, flare-ups of inflammation, bacterial infections in the bile ducts, ordinary blockages, or jaundice can all temporarily spike your CA 19-9 levels.

Why is my CA 19-9 test always paired with an ultrasound or MRCP?

A blood test alone cannot confirm or rule out cancer, as both false positives and false negatives can occur. Combining the CA 19-9 test with a visual scan of your bile ducts, like an ultrasound or MRCP, gives your doctor the most accurate information.

What does it mean if I am Lewis negative for the CA 19-9 test?

About 5 to 10 percent of people lack a specific blood protein called the Lewis antigen, meaning their bodies physically cannot produce CA 19-9. If you are Lewis negative, your test results will always be near zero, making the blood test an ineffective cancer screen for you.

What happens if my CA 19-9 levels are unusually high?

If your levels are high and you have an infection or jaundice, your doctor may wait for it to clear and retest. If levels remain consistently high or scans look suspicious, you may need more detailed imaging or an ERCP procedure to evaluate your bile ducts.

Curated prompts to bring to your next appointment.

1.What is my personal baseline for CA 19-9, and what kind of trend or jump would you consider concerning?
2.Given my medical history, is it better to pair my CA 19-9 tests with an ultrasound or an MRCP scan?
3.If I am currently experiencing an infection or jaundice, should we delay my CA 19-9 blood test until my symptoms clear?
4.Do you know if I am 'Lewis blood type negative' and how that might affect my CA 19-9 results?
5.If my CA 19-9 levels come back elevated, what exact steps will we take to figure out if it is just inflammation or something more serious?

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

What is the Best Diet for Primary Sclerosing Cholangitis?What Experimental Treatments Are in PSC Clinical Trials?What is the Difference Between IgG4-SC and PSC?Why is Balloon Dilation Preferred Over Stents for PSC?What Does a FibroScan Score Over 10.5 kPa Mean for PSC?When Should PSC Patients Have Gallbladder Polyps Removed?Is High-Dose URSO Safe for Primary Sclerosing Cholangitis?PSC: Can Recurrent Cholangitis Raise My MELD Score?Will PSC Come Back After a Liver Transplant? Explained What Is the Difference Between Small & Large Duct PSC?What Are the Third-Line Treatments for Severe PSC Itching?When to Take Cholestyramine with Other PSC Medications Why Do You Need A Colonoscopy For PSC Without Symptoms?

References (15)

1
Impact on follow-up strategies in patients with primary sclerosing cholangitis.
Bergquist A, Weismüller TJ, Levy C, et al.
Liver international : official journal of the International Association for the Study of the Liver 2023; (43(1)):127-138 doi:10.1111/liv.15286.
PMID: 35535655
2
Cancer risk in primary sclerosing cholangitis: Epidemiology, prevention, and surveillance strategies.
Fung BM, Lindor KD, Tabibian JH
World journal of gastroenterology 2019; (25(6)):659-671 doi:10.3748/wjg.v25.i6.659.
PMID: 30783370
3
Longitudinal analysis of CA19-9 reveals individualised normal range and early changes before development of biliary tract cancer in patients with primary sclerosing cholangitis.
Wannhoff A, Brune M, Knierim J, et al.
Alimentary pharmacology & therapeutics 2019; (49(6)):769-778 doi:10.1111/apt.15146.
PMID: 30687954
4
Primary Sclerosing Cholangitis-Associated Cholangiocarcinoma: From Pathogenesis to Diagnostic and Surveillance Strategies.
Catanzaro E, Gringeri E, Burra P, Gambato M
Cancers 2023; (15(20)) doi:10.3390/cancers15204947.
PMID: 37894314
5
Primary Sclerosing Cholangitis: A Concise Review of Diagnosis and Management.
Fricker ZP, Lichtenstein DR
Digestive diseases and sciences 2019; (64(3)):632-642 doi:10.1007/s10620-019-05484-y.
PMID: 30725292
6
Diagnostic Accuracy of Serum CA19-9 in Patients with Cholangiocarcinoma: A Systematic Review and Meta-Analysis.
Liang B, Zhong L, He Q, et al.
Medical science monitor : international medical journal of experimental and clinical research 2015; (21()):3555-63 doi:10.12659/msm.895040.
PMID: 26576628
7
Surveillance of primary sclerosing cholangitis with ERC and brush cytology: risk factors for cholangiocarcinoma.
Boyd S, Mustonen H, Tenca A, et al.
Scandinavian journal of gastroenterology 2017; (52(2)):242-249 doi:10.1080/00365521.2016.1250281.
PMID: 27806633
8
Cholangiocarcinoma Surveillance Recommendations in Patients with Primary Sclerosing Cholangitis.
Saca D, Flamm SL
Clinics in liver disease 2024; (28(1)):183-192 doi:10.1016/j.cld.2023.07.010.
PMID: 37945159
9
Incidence of Hepatobiliary Malignancies in Primary Sclerosing Cholangitis: Systematic Review and Meta-analysis.
Souza M, Lima LCV, Al-Sharif L, Huang DQ
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2025; (23(10)):1695-1709.e13 doi:10.1016/j.cgh.2024.09.037.
PMID: 39709139
10
An update on cancer risk and surveillance in primary sclerosing cholangitis.
Horsley-Silva JL, Rodriguez EA, Franco DL, Lindor KD
Liver international : official journal of the International Association for the Study of the Liver 2017; (37(8)):1103-1109 doi:10.1111/liv.13354.
PMID: 28028930
11
Autoimmune Disorders of the Liver and Biliary Tract.
Anderson CM, Welle CL, Ludwig DR, et al.
Radiographics : a review publication of the Radiological Society of North America, Inc 2025; (45(4)):e240126 doi:10.1148/rg.240126.
PMID: 40111901
12
Follow-up magnetic resonance imaging/3D-magnetic resonance cholangiopancreatography in patients with primary sclerosing cholangitis: challenging for experts to interpret.
Zenouzi R, Liwinski T, Yamamura J, et al.
Alimentary pharmacology & therapeutics 2018; (48(2)):169-178 doi:10.1111/apt.14797.
PMID: 29741240
13
Inflammation But Not Biliary Obstruction Is Associated With Carbohydrate Antigen 19-9 Levels in Patients With Primary Sclerosing Cholangitis.
Wannhoff A, Rupp C, Friedrich K, et al.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2015; (13(13)):2372-9.
PMID: 26192140
14
The Detection of Cholangiocarcinoma in Primary Sclerosing Cholangitis Patients: Single Center Experience.
Kuzu UB, Ödemiş B, Suna N, et al.
Journal of gastrointestinal cancer 2016; (47(1)):8-14 doi:10.1007/s12029-015-9777-1.
PMID: 26537791
15
The Diagnostic Value of the CA19-9 and Bilirubin Ratio in Patients with Pancreatic Cancer, Distal Bile Duct Cancer and Benign Periampullary Diseases, a Novel Approach.
Boyd LNC, Ali M, Kam L, et al.
Cancers 2022; (14(2)) doi:10.3390/cancers14020344.
PMID: 35053506

This page provides educational information about CA 19-9 testing for PSC patients and does not replace professional medical advice. Always discuss your specific screening results and surveillance schedule with your gastroenterologist or hepatologist.

Get notified when new evidence is published on Primary sclerosing cholangitis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.